Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study
Allergy · 2026
DOI: 10.1111/all.16640 ↗At a glance
Randomisierte kontrollierte Studie in Allergy, 2026. Written by Janice A Layhadi and 18 co-authors. Institution: National Heart and Lung Institute, Imperial College London, London, UK. Major MEDLINE topics: Rhinitis, Allergic, Seasonal, Poaceae, Immunity, Humoral, Allergens. Cited 1 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: Allergy Therapeutics.
Abstract (original language)
Background
A short‐course pre‐seasonal subcutaneous injection of PQ Grass is clinically effective for the treatment of allergic rhinitis, though its mechanism remains unclear. The aim of the study was to interrogate immunological mechanisms induced by PQ Grass conventional and extended regimens.
Methods
A RDBPC exploratory field study involving participants that either received injections of PQ Grass with a cumulative dose of 27,600 SU conventional (six once weekly injections) or extended regimen (three once weekly injections followed by three once monthly injections) or placebo containing microcrystalline tyrosine (MCT) (placebo + MCT) or saline (placebo) was performed. Humoral, cellular, and molecular responses were assessed at baseline (V1), end of treatment, prior to grass pollen season (V12) and end of pollen season (V15). Immunoglobulin analyses and cellular/gene microarray analyses were performed in the sub‐study cohort consisting of PQ Grass Conventional ( n = 25 and n = 10, respectively), PQ Grass Extended ( n = 26 and n = 10, respectively), Placebo with MCT ( n = 13 and n = 5, respectively), and Placebo (saline; n = 12 and n = 5, respectively).
Results
Both PQ Grass regimens, conventional and extended, were associated with improvement in total combined scores (TCS) with a relative difference of −35.0% ( p = 0.03) and −40.8% ( p = 0.01) against placebo with MCT, respectively. Both PQ Grass treatment regimens were associated with increases in the sIgG 4 /sIgE ratio (all, p < 0.05) and induction of IgA 1 (all, p < 0.05) and IgA 2 (all, p < 0.01) compared to placebo groups. Nasal fluid ( p < 0.01) and serum ( p < 0.05) blocking antibodies are functional and have the capacity to inhibit allergen‐IgE complex formation and binding to B cells in the PQ Grass groups. In vitro cellular and microarray gene analyses demonstrated that the extended PQ Grass regimen was more proficient in modulating the immune response towards a tolerogenic milieu by dampening pro‐inflammatory type 2 immune response and the associated cytokines ( p < 0.05), immune deviation towards a Th1 response ( p < 0.05), and induction of FOXP3 + Treg cells ( p < 0.05).
Conclusions
For the first time, we highlight differential mechanisms of tolerance induction by PQ Grass, with the extended regimen being superior in modulating T cell compartments. Trail Registration Trial number: PQGrass309, EudraCT number: 2020‐000408‐13, Clinicaltrials.gov identifier: NCT04687059, and NCT05540717
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Heart and Lung Institute, Imperial College London, London, UK.
- Allergy Therapeutics PLC, Worthing, UK.
- Bencard Allergie GmbH, Munich, Germany.
ORCID profiles: Janice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, Elizabeth Palmer, Lily Y D Wu, Sean T Keane, William T Fulton, Prista Hikmawati, Xun Meng, Kemi Oluwayi, Katarzyna Lis, Oliver Armfield, Murray A Skinner, Matthew D Heath, Matthias F Kramer, Mohamed H Shamji
Funding
- Allergy Therapeutics
Cite
APA
Layhadi, J. A., Starchenka, S., De Kam, P. J., Palmer, E., Wu, L. Y. D., Keane, S. T., Fulton, W. T., Hikmawati, P., Meng, X., Filipaviciute, P., Cutrina Pons, A., Oluwayi, K., Lis, K., Armfield, O., Skinner, M. A., Heath, M. D., Hewings, S. J., Kramer, M. F., & Shamji, M. H. (2026). Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. https://doi.org/10.1111/all.16640
Vancouver
Layhadi JA, Starchenka S, De Kam PJ, Palmer E, Wu LYD, Keane ST, et al. Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. 2026. doi:10.1111/all.16640
BibTeX
@article{Layhadi2026,
author = {Layhadi, Janice A and Starchenka, Sviatlana and De Kam, Pieter-Jan and Palmer, Elizabeth and Wu, Lily Y D and Keane, Sean T and Fulton, William T and Hikmawati, Prista and Meng, Xun and Filipaviciute, Paulina and Cutrina Pons, Anna and Oluwayi, Kemi and Lis, Katarzyna and Armfield, Oliver and Skinner, Murray A and Heath, Matthew D and Hewings, Simon J and Kramer, Matthias F and Shamji, Mohamed H},
title = {Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.16640}
}
EUVIMED